Biomarkers of Renal Tumor Burden and Progression in TSC
Abstract
Renal lesions occur commonly in people with TSC and can cause significant morbidity and mortality [1]. Although most solid renal lesions of TSC are benign angiomyolipoma (AML), some are in fact cancerous. Moreover, rapidly growing AMLs can be life threatening when abnormal blood vessels rupture [2]. Based on the hypothesis that renal tumor growth is associated with measurable changes in urine composition and on the knowledge that angiogenesis is essential for tumor expansion [3, 4], we have predicted that factors associated with angiogenesis and with renal injury will increase during periods of TSC-associated renal tumor growth. We are testing this candidate driven approach to identify factors in urine or serum that reflect renal tumor burden and whose concentrations change as tumors grow. This project can be described in two aims. (A) Monitor the progression of TSC renal disease by combining prospective data collection with retrospective chart review of a large population of TSC patients with respect to gender, age, patient size, TSC genotype, renal lesions (e.g. lesion number, appearance and growth rates) and renal function parameters (e.g. blood pressure, serum chemistries, urinalysis and urine chemistries). (B) Measure soluble growth factors, angiogenesis factors and renal injury molecules in urine and serum samples from patients with TSC and evaluate these candidates as surrogate markers of renal tumor burden and growth.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2013
- Accession Number
- ADA591994
Entities
People
- Elahna Paul
Organizations
- Massachusetts General Hospital